Silence Therapeutics (LON:SLN) Shares Cross Below 200 Day Moving Average of $535.00

Silence Therapeutics plc (LON:SLNGet Rating) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 535 ($6.53) and traded as low as GBX 512 ($6.25). Silence Therapeutics shares last traded at GBX 535 ($6.53), with a volume of 913,528 shares.

Silence Therapeutics Stock Performance

The company has a current ratio of 4.52, a quick ratio of 4.36 and a debt-to-equity ratio of 0.80. The company has a market cap of £480.35 million and a P/E ratio of -11.01. The business’s 50 day simple moving average is GBX 535 and its 200 day simple moving average is GBX 535.

Silence Therapeutics Company Profile

(Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.

Featured Articles

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.